TTK Healthcare Limited (TTKHLTCARE) AI Stock Analysis

• Market Cap: ₹14.22B
• Dividend Yield: 0.95%
• Average Volume (3M): 82.00
• Price to Earnings (P/E): 21.5
• Beta (1Y): 0.79
• Revenue Growth: 6.98%
• EPS Growth: -17.11%
• Country: IN
• Employees: 1,316
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 14.43
• Shares Outstanding: 14,130,333
• 10 Day Avg. Volume: 50
• 30 Day Avg. Volume: 82
• PEG Ratio: 0.68
• Price to Book (P/B): 1.57
• Price to Sales (P/S): 1.91
• P/FCF Ratio: -99.33
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 71 Outperform
• Price Target: ₹1,313.00 ▲(27.60% Upside)

TTK Healthcare Limited's overall stock score is driven by its strong financial stability and moderate technical indicators. While the company shows solid revenue growth and a healthy balance sheet, cash flow management issues and a fair valuation limit the score. The absence of recent earnings call insights and notable corporate events means these factors did not influence the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates robust market demand and effective sales strategies, enhancing long-term business sustainability.

Balance Sheet Health

A strong balance sheet with low leverage provides financial stability and flexibility to invest in growth opportunities.

Product and Market Diversification

Diversified operations across multiple sectors reduce risk and allow the company to capitalize on various growth opportunities.

Negative Factors

Cash Flow Management

Ongoing cash flow challenges may hinder the company's ability to fund operations and growth initiatives, impacting long-term viability.

Declining EBITDA Margin

Decreasing margins may indicate rising costs or inefficiencies, which could erode profitability if not addressed.

Earnings Volatility

Negative EPS growth reflects earnings volatility, which can undermine investor confidence and limit capital raising potential.

TTK Healthcare Limited Business Overview & Revenue Model

Company Description

TTK Healthcare Limited engages in the animal welfare and human pharma product, consumer product, medical device, protective device, and food businesses in India and internationally. Its Animal Welfare segment deals in various therapeutic formulations and feed supplements for veterinary use. The company's Consumer Products segment is involved in the marketing and distribution of Woodward's Gripewater, EVA range of cosmetics, Good Home range of scrubbers, air fresheners, etc. its Medical Devices segment manufactures and distributes artificial heart valves; and develops orthopedic implants and instruments. The company's Protective Devices segment manufactures and markets male contraceptives and other allied products. Its Foods segment engages in the manufacturing and marketing of food products, including potato and cereal based pellets. The company's Others segment prints and publishes maps and atlases. Its Human Pharma segment deals in herbal and allopathic formulations for human use. The company was incorporated in 1958 and is headquartered in Chennai, India. TTK Healthcare Limited is a subsidiary of TT Krishnamachari & Co., Ltd.

How the Company Makes Money

TTK Healthcare generates revenue through multiple streams, including the sale of pharmaceutical products, consumer healthcare items, and medical devices. The company’s revenue model is primarily based on direct sales to hospitals, pharmacies, and retail chains as well as distribution through various channels. Significant partnerships with healthcare institutions and collaborations with international pharmaceutical companies also contribute to its earnings. Additionally, the company invests in research and development to innovate and expand its product offerings, further enhancing its revenue potential.

TTK Healthcare Limited Financial Statement Overview

Summary

TTK Healthcare Limited exhibits solid financial performance with strong revenue growth and financial stability. The company has a robust balance sheet with low leverage and high equity ratio. However, challenges in cash flow management, such as negative free cash flow and operating cash flow, need to be addressed.

Income Statement

TTK Healthcare Limited has demonstrated a strong revenue growth trajectory, with a notable increase in total revenue from 2024 to 2025. The gross profit margin is robust, showcasing effective cost management. However, the declining EBITDA margin suggests potential increases in operational costs or inefficiencies.

Balance Sheet

The company maintains a healthy balance sheet with a low debt-to-equity ratio and a strong equity ratio, indicating financial stability and low leverage. The high ROE reflects efficient use of equity to generate profits.

Cash Flow

Cash flow analysis reveals challenges, with negative free cash flow and operating cash flow figures. Although there is an improvement in free cash flow growth year-on-year, the negative operating cash flow to net income ratio highlights ongoing cash management issues.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	8.20B	8.73B	7.48B	7.25B	5.99B	4.76B
Gross Profit	5.54B	5.04B	4.07B	3.77B	3.09B	1.38B
EBITDA	1.03B	1.06B	999.35M	796.81M	406.58M	373.52M
Net Income	630.81M	816.57M	628.42M	6.40B	415.88M	464.41M
Balance Sheet
Total Assets	0.00	12.81B	12.01B	11.70B	5.59B	4.94B
Cash, Cash Equivalents and Short-Term Investments	8.55B	8.55B	8.45B	8.47B	2.73B	2.27B
Total Debt	0.00	242.19M	228.11M	273.29M	222.13M	191.44M
Total Liabilities	-10.65B	2.16B	2.00B	2.17B	2.29B	2.00B
Stockholders Equity	10.65B	10.65B	10.01B	9.53B	3.30B	2.95B
Cash Flow
Free Cash Flow	0.00	-168.16M	-153.27M	-377.75M	385.02M	946.88M
Operating Cash Flow	0.00	-39.76M	-49.43M	-260.76M	449.96M	964.21M
Investing Cash Flow	0.00	201.03M	284.94M	329.59M	-305.47M	-772.39M
Financing Cash Flow	0.00	-180.81M	-219.11M	-124.26M	-51.77M	-171.56M

TTK Healthcare Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1029.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TTKHLTCARE, the sentiment is Negative. The current price of 1029 is above the 20-day moving average (MA) of 1028.57, below the 50-day MA of 1078.76, and below the 200-day MA of 1179.18, indicating a bearish trend. The MACD of -22.37 indicates Positive momentum. The RSI at 26.83 is Positive, neither overbought nor oversold. The STOCH value of 14.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:TTKHLTCARE.

TTK Healthcare Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMRUTANJAN	72 Outperform	₹18.34B	31.98	―	0.68%	7.36%	19.31%
TTKHLTCARE	71 Outperform	₹14.22B	21.46	―	0.95%	6.98%	-17.11%
SMSPHARMA	65 Neutral	₹31.79B	35.37	―	0.13%	11.91%	36.92%
VIMTALABS	64 Neutral	₹25.85B	32.74	―	0.16%	17.05%	56.84%
WINDLAS	62 Neutral	₹15.88B	23.38	―	0.71%	19.34%	9.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BAJAJHCARE	51 Neutral	₹12.50B	27.27	―	0.24%	13.04%	―

TTK Healthcare Limited Corporate Events

TTK Healthcare Seeks Shareholder Nod via E-Voting to Appoint New Independent Director

TTK Healthcare Limited has launched a postal ballot process to seek shareholder approval via special resolution for the appointment of Mr. V. Sundaresan as an Independent Director for a five-year term effective 22 December 2025. The company is conducting the process entirely through remote e-voting provided by CDSL, with notices emailed to eligible shareholders as of 19 December 2025 and voting scheduled between 26 December 2025 and 24 January 2026, underscoring its adherence to regulatory requirements and emphasis on transparent, digital-first corporate governance.

TTK Healthcare Board Appoints New Independent Director, Seeks Shareholder Nod via Postal Ballot

TTK Healthcare Limited’s board has approved the appointment of V. Sundaresan as an Additional Independent Director for a five-year term starting 22 December 2025, subject to shareholder approval via a special resolution. To secure this approval, the company will conduct a postal ballot through remote e-voting, appointing A K Jain & Associates as the scrutinizer to oversee the process, underscoring its emphasis on transparent governance and regulatory compliance under SEBI’s listing obligations.